

JEMTAC Journal of Emergency Medicine Trauma & Acute Care A PEER REVIEWED JOURNAL

**OPEN ACCESS** 

<sup>1</sup>Pharmacy Executive Office, Hamad Medical Corporation, Doha, Qatar <sup>2</sup>Pharmacy Department, Al Wakra Hospital, Doha, Qatar <sup>3</sup>Department of Obstetrics, WWRC, Doha, Qatar <sup>4</sup>Cardiology Research, Hamad Medical Corporation, Doha, Qatar <sup>5</sup>College of Pharmacy, Qatar University, Doha, Qatar

\*Email: bthomas28@hamad.qa

#### http://dx.doi.org/ 10.5339/jemtac.2022.qhc.21

Submitted: 27 July 2021 Accepted: 6 September 2021 Publication date: 15 January 2022 © 2022 Al Hail, Thomas, Elkassem, Al Anany, Tarannum, Al Hail, Singh, Stewart, Abdulrouf, licensee HBKU Press. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.



## Qatar Health 2022 Conference

# Behavioral determinants potentially influencing COVID-19 vaccine acceptance among pharmacy professionals in Qatar: a nationwide survey using the Theoretical Domains Framework

Moza Al Hail<sup>1</sup>, Binny Thomas<sup>1,\*</sup>, Wessam Elkassem<sup>1</sup>, Rasha Al Anany<sup>2</sup>, Asma Tarannum<sup>3</sup>, Fatema Al Hail<sup>3</sup>, Rajvir Singh<sup>4</sup>, Derek Stewart<sup>5</sup>, Pallivalapila Abdulrouf<sup>1</sup>

## ABSTRACT

**Background:** There is a paucity of robust, theory-based research investigating vaccination behavior.<sup>1</sup> Using Theoretical Domains Framework (TDF), the study aimed to explore the key behavioral determinants influencing vaccine behavior among pharmacy professionals in Qatar.

**Methods:** A cross-sectional online survey of pharmacy professionals was conducted in April 2021. Survey items included questions related to demographics, vaccination behavior, and behavioral 'determinants' influencing vaccination (Likert statements, TDF items). The draft questionnaire was reviewed for face and content validity with experts and piloted among 80 participants. The sample size was calculated (n = 353) using the Raosoft online calculator. Data were analyzed using descriptive and inferential statistics and Principal component analysis (PCA) of TDF items.<sup>2,3</sup>

**Results:** The response rate was 37.40% (1,065/2,400). The majority expressed willingness to receive the COVID-19 vaccines. Participants who refused the influenza vaccine in the past were more likely to refuse the COVID-19 vaccines too ( $\chi_2(1) = 12.6$ , chi-square; p < 0.001). The mean (SD) overall percentage score of behavioral determinants influencing vaccine acceptance and advocacy were 31.2  $\pm$  19.6 and 36.5  $\pm$  28.2 (on a scale from -100 to 100). Vaccine acceptance was lower among those who refused any vaccines in the past (33.2  $\pm$  18.9 vs 28.7  $\pm$  20.1; p < 0.001) (Table 1). The main barriers to vaccine acceptance were safety, speed of development, and cultural influences. PCA identified 'belief of consequence and emotions (fear and anxiety) as more negative determinant (-1.4  $\pm$  42.1) potentially influencing vaccine acceptance behavior (Table 2). Although most participants considered it as their professional duty to advocate the use of vaccines, they were unsure if patients will accept their recommendations.

**Conclusion:** Most participants expressed an interest to receive the COVID-19 vaccines and considered it as their professional duty to recommend the use of the vaccine. However, they were unsure if patients would accept their advice. Study findings will assist to develop behavior change interventions targeting individuals.

*Keywords:* COVID-19 vaccine, Vaccine acceptance and advocacy behaviour, Pharmacy professionals, Theoretical Domains Framework, Principal Component Analysis (PCA)

Cite this article as: Al Hail M, Thomas B, Elkassem W, Al Anany R, Tarannum A, Al Hail F, Singh R, Stewart D, Abdulrouf P. Behavioral determinants potentially influencing COVID-19 vaccine acceptance among pharmacy professionals in Qatar: a nationwide survey using the Theoretical Domains Framework, *Journal of Emergency Medicine, Trauma & Acute Care* 2022:21 http://dx.doi.org/10.5339/jemtac.2022.qhc.21

		Accept: (-100 to 10		Advocacy (-100 to 100 scale)	
	Variable (N=927)	Mean SD	p-value	Mean SD	p-value
Gender	Male (n=531)	33.7 ± 18.5	<0.001	40.8 ± 26.3	<0.001
	Female (n=396)	27.8 ± 20.6	<0.001	30.9 ± 29.5	
Age	<25 years (n=27)	28.1 ± 19.7		30.1 ±26.6	
	25 - 34 years (n=466)	31.6 ± 19.5	>0.05	36.1 ± 28.3	
	35 - 44 years (n=319)	29.9 ± 19.7		34.7 ± 26.5	
	45 - 60 years (n=109)	32.6 ± 19.6		43.4 ± 31.2	
	> 60 years (n=6)	44.8 ± 20.4		67.7 ± 32.3	
Country of origin	Eastern Mediterranean Region (n=425)	28.6 ± 20.3	<0.001	32.1 ± 29.8	<0.001
	African region (n=13)	30.2 ± 25.3		24.7 ± 34.4	
	Region of the Americas (n=22)	21.4 ± 15.5		36.7 ± 28.4	
	European Region (n=8)	38.7 ± 31.9		39.1 ± 32.8	
	Southeast Asian region (n=409)	33.8 ± 17.7		42.1 ± 24.6	
	Western Pacific Region (n=50)	34.8 ± 22.7		32.9 ± 30.9	
Highest academic qualification	Diploma (n=165)	31.9 ± 20.6		39.4 ± 27.7	>0.05
	BSc Pharm/BPharm (n=456)	31.8 ± 19.8		36.3 ± 26.1	
	Masters or equivalent (n=172)	30.5 ± 18.2	>0.05	36.2 ± 26.1	
	PgDip/PgCert (n=34)	41.2 ± 28.8	>0.05	41.2 ± 28.7	
	PharmD (n=96)	32.1 ± 26.5		32.1 ± 26.5	
	PhD (n=4)	25 ± 37.4		25 ± 37.4	
	< 1 year (n=30)	33.6 ± 18.8		37.1 ± 30.7	>0.05
Registered	1-5 years (n=242)	31.2 ± 19.1		35.6 ± 28.5	
pharmacist	6 – 10 years (n=177)	31.2 ± 21.6	>0.05	37.8 ± 28.5	
(years)	11 – 15 years (n=258)	29.9 ±19.2		33.5 ± 28.4	
	> 15 years (n=220)	30.5 ± 18.3		40.2 ± 31.5	
Practice setting	Hospital Pharmacists (n=493)	28.8 ± 20.2		33.9 ± 29.1	<0.014
	Community Pharmacists (n=383)	33.4 ±18.9	<0.001	39.1 ± 27.4	
	Pharmacists in polyclinics/clinics (n=51)	40.1 ± 13.3		41.8 ± 22.7	
Current role	Pharmacy technician (n=156)	31.7 ± 19.9		39.2 ± 27.1	>0.05
	Staff pharmacists (n=459)	31.1 ± 19.2		35.1 ± 28.3	
	Clinical Pharmacist/specialists (n=94)	27.9 ± 20.7	>0.05	33.9 ± 25.9	
	Pharmacy supervisors/managers (n=218)	32.3 ± 19.7		38.9 ± 29.4	

## Table 1. Vaccination behavior (acceptance and advocacy).

### Table 2. Principal component analysis of vaccine acceptance behavior.

Component 3: Belief of consequence and emotions (Fear and anxiety)	Strongly disagree n (%)	Disagree n (%)	Neutral n (%)	Agree n (%)	Strongly agree n (%)
$^{\ast\ast\ast}I$ am worried about the speed of development and testing of COVID-19 vaccine	48	208	275	297	99
	(5.2)	(22.4)	(29.7)	(32)	(10.7)
***I am not satisfied with the evidence behind the	71	283	300	192	80
safety of COVID-19 vaccines	(7.7)	(30.5)	(32.4)	(20.7)	(8.6)
***I am worried about the side effects of the novel	64	214	267	272	110
COVID -19 vaccine	(6.9)	(23.1)	(28.8)	(29.3)	(11.9)
**I am worried that mRNA vaccines can change the	101	232	391	139	64
genetic makeup of people receiving it?	(10.9)	(25)	(42.2)	(15)	(6.9)

Cronbach's alpha 0.79 Mean (SD)=-1.4±42.1 \*\*\* reverse scored

**Ethical approval/IRB statement:** The study received ethical approval from Hamad Medical Corporation's Medical Research Center Qatar (MRC-12-21-131).

#### REFERENCES

- [1] Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X, et al. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. *BMJ.* 2020 Dec 15;371m4704.
- [2] Atkins L, Francis J, Islam R, O'Connor D, Patey A, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. *Implementation Science*. 2017;12(1):1–8.
- [3] Bro R, Smilde AK. Principal component analysis. Analytical methods. 2014;6(9):2812-31.